A comparison of health status in patients meeting alternative definitions for chronic fatigue syndrome/myalgic encephalomyelitis

Health and Quality of Life Outcomes

Sonya M Marshall-Gradisnik²  Donald R Staines¹  Teilah K Huth²  Sharni L Hardcastle²  Ekua W Brenu²  Samantha C Johnston² 

[1] Gold Coast Public Health Unit, Queensland Health, Robina, QLD, Australia;Griffith Health Institute, School of Medical Sciences, National Centre for Neuroimmunology and Emerging Diseases, Griffith University, Parklands, QLD 4222, Australia

关键词: Health-related quality of life;    Myalgic encephalomyelitis;    Disability;    Chronic fatigue syndrome;   

Others  :  814869
DOI  :  10.1186/1477-7525-12-64

 received in 2013-09-18, accepted in 2014-04-26,  发布年份 2014

【 摘 要 】

Background

Several diagnostic definitions are available for Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME) that varies significantly in their symptom criteria. This pilot study was conducted to determine whether simple biological and clinical measures differed between CFS/ME patients meeting the 1994 Centres for Disease Control and Prevention (CDC) criteria, the International Consensus Criteria (ICC), as well as healthy controls.

Methods

A total of 45 CFS/ME patients and 30 healthy controls from the South East Queensland region of Australia provided a blood sample, reported on their current symptoms, as well as aspects of their physical and social health using the Short-Form Health Survey (SF-36), and the World Health Organisation Disability Adjustment Schedule 2.0 (WHO DAS 2.0). Differences were examined using independent sample t-testing.

Results

Patients fulfilling the ICC definition reported significantly lower scores (p < 0.05) for physical functioning, physical role, bodily pain, and social functioning than those that only fulfilled the 1994 CDC definition. ICC patients reported significantly greater (p < 0.05) disability across all domains of the WHO DAS 2.0.

Conclusions

These preliminary findings suggest that the ICC identifies a distinct subgroup found within patients complying with the 1994 CDC definition, with more severe impairment to their physical and social functioning.

【 授权许可】

   
2014 Johnston et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Holmes GP, Kaplan JE, Gantz NM, Komaroff AL, Schonberger LB, Straus SE, Jones JF, Dubois RE, Cunningham-Rundles C, Pahwa S, Tosato G, Zegans LS, Purtilo DT, Brown N, Schooley RT, Brus I: Chronic fatigue syndrome: a working case definition. Ann Intern Med 1988, 108(3):387-389.
• [2]Hopkins J: Bornholm disease. Br Med J 1950, 1(4664):1230.
• [3]Acheson E: The clinical syndrome variously called benign myalgic encephalomyelitis, Iceland disease and epidemic neuromyasthenia. Am J Med 1959, 26(4):569-595.
• [4]Crowley N, Nelson M, Stovin S: Epidemiological aspects of an outbreak of encephalomyelitis at the Royal Free Hospital, London, in the summer of 1955. J Hygiene 1957, 55(1):102-122.
• [5]Buchwald D, Goldenberg DL, Sullivan JL, Komaroff AL: The “chronic, active epstein‒barr virus infection” syndrome and primary fibromyalgia. Arthritis & Rheumatism 1987, 30(10):1132-1136.
• [6]Carruthers BM, van de Sande MI, De Meirleir KL, Klimas NG, Broderick G, Mitchell T, Staines D, Powles AC, Speight N, Vallings R, Bateman L, Baumgarten-Austrheim B, Bell DS, Carlo-Stella N, Chia J, Darragh A, Jo D, Lewis D, Light AR, Marshall-Gradisbik S, Mena I, Mikovits JA, Miwa K, Murovska M, Pall ML, Stevens S: Myalgic encephalomyelitis: international consensus criteria. J Intern Med 2011, 270(4):327-338.
• [7]Carruthers BM, Jain AK, De Meirleir K, Paterson DL, Klimas N, Lerner AM, Bested AC, Flor-Henry P, Joshi P, Powles AC, Sherkey JA, van de Sande M: Myalgic encephalomyelitis/chronic fatigue syndrome: clinical working case definition, diagnostic and treatment protocols. J Chronic Fatigue Syndrome 2003, 11(1):7-36.
• [8]Fukuda K, Straus SE, Hickie I, Sharpe MC, Dobbins JG, Komaroff A: The chronic fatigue syndrome: a comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group. Ann Intern Med 1994, 121(12):953-959.
• [9]Sharpe MC, Archard LC, Banatvala JE, Borysiewicz LK, Clare AW, David A, Edwards RH, Hawton KE, Lambert HP, Lane RJ: A report–chronic fatigue syndrome: guidelines for research. J R Soc Med 1991, 84(2):118-121.
• [10]Ho-Yen DO: Patient management of post-viral fatigue syndrome. Br J Gen Pract 1990, 40(330):37-39.
• [11]Lloyd AR, Hickie I, Boughton CR, Spencer O, Wakefield D: Prevalence of chronic fatigue syndrome in an Australian population. Med J Aust 1990, 153(9):522-528.
• [12]Reeves WC, Wagner D, Nisenbaum R, Jones JF, Gurbaxani B, Solomon L, Papanicolaou DA, Unger ER, Vernon SD, Heim C: Chronic fatigue syndrome–a clinically empirical approach to its definition and study. BMC Med 2005, 3:19. BioMed Central Full Text
• [13]Johnston S, Brenu EW, Staines DR, Marshall-Gradisnik S: The adoption of chronic fatigue syndrome/myalgic encephalomyelitis case definitions to assess prevalence: a systematic review. Ann Epidemiol 2013, 23(6):371-376.
• [14]Jason LA, Richman JA: How science can stigmatize: the case of chronic fatigue syndrome. J Chronic Fatigue Syndrome 2007, 14(4):85-103.
• [15]Reeves WC, Lloyd A, Vernon SD, Klimas N, Jason LA, Bleijenberg G, Evengard B, White PD, Nisenbaum R, Unger ER: Identification of ambiguities in the 1994 chronic fatigue syndrome research case definition and recommendations for resolution. BMC Health Serv Res 2003, 3(1):25. BioMed Central Full Text
• [16]Nacul LC, Lacerda EM, Pheby D, Campion P, Molokhia M, Fayyaz S, Leite JC, Poland F, Howe A, Drachler ML: Prevalence of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) in three regions of England: a repeated cross-sectional study in primary care. BMC Med 2011, 9:91. BioMed Central Full Text
• [17]Jason LA, Torres-Harding SR, Jurgens A, Helgerson J: Comparing the Fukuda et al. criteria and the Canadian case definition for chronic fatigue syndrome. J Chronic Fatigue Syndrome 2004, 12(1):37-52.
• [18]Sullivan PF, Pedersen NL, Jacks A, Evengard B: Chronic fatigue in a population sample: deifnitions and heterogeneity. Psychol Med 2005, 35(9):1337-1348.
• [19]Chen R, Liang FX, Moriya J, Yamakawa J, Sumino H, Kanda T, Takahashi T: Chronic fatigue syndrome and the central nervous system. J Int Med Res 2008, 36(5):867-874.
• [20]Cook DB, Lange G, DeLuca J, Natelson BH: Relationship of brain MRI abnormalities and physical functional status in chronic fatigue syndrome. Int J Neurosci 2001, 107(1–2):1-6.
• [21]Streeten DH, Thomas D, Bell DS: The roles of orthostatic hypotension, orthostatic tachycardia, and subnormal erythrocyte volume in the pathogenesis of the chronic fatigue syndrome. Am J Med Sci 2000, 320(1):1-8.
• [22]Tirelli U, Chierichetti F, Tavio M, Simonelli C, Bianchin G, Zanco P, Ferlin G: Brain positron emission tomography (PET) in chronic fatigue syndrome: preliminary data. Am J Med 1998, 105(3A):54S-58S.
• [23]Fletcher MA, Zeng XR, Maher K, Levis S, Hurwitz B, Antoni M, Broderick G, Klimas NG: Biomarkers in chronic fatigue syndrome: evaluation of natural killer cell function and dipeptidyl peptidase IV/CD26. PLoS One 2010, 5(5):e10817.
• [24]Lorusso L, Mikhaylova SV, Capelli E, Ferrari D, Ngonga GK, Ricevuti G: Immunological aspects of chronic fatigue syndrome. Autoimmun Rev 2009, 8(4):287-291.
• [25]Mihaylova I, DeRuyter M, Rummens J-L, Bosmans E, Maes M: Decreased expression of CD69 in chronic fatigue syndrome in relation to inflammatory markers: evidence for a severe disorder in the early activation of T lymphocytes and natural killer cells. Neuro Endocrinol Lett 2007, 28(4):477.
• [26]Klimas NG, Salvato FR, Morgan R, Fletcher MA: Immunologic abnormalities in chronic fatigue syndrome. J Clin Microbiol 1990, 28(6):1403-1410.
• [27]Myhill S, Booth NE, McLaren-Howard J: Chronic fatigue syndrome and mitochondrial dysfunction. Int J Clin Exp Med 2009, 2(1):1.
• [28]Pieczenik SR, Neustadt J: Mitochondrial dysfunction and molecular pathways of disease. Exp Mol Pathol 2007, 83(1):84-92.
• [29]Behan W, More I, Behan P: Mitochondrial abnormalities in the postviral fatigue syndrome. Acta Neuropathol 1991, 83(1):61-65.
• [30]Friedberg F, Bateman L, Bested AC, Davenport T, Friedman KJ, Gurwitt A, Leonard LA, Lapp CW, Stevens SR, Underhill RA, Vallings R: ME/CFS: A Primer for Clinical Practitioners. Chicago, USA: International Association for Chronic Fatigue Syndrome/Myalgic Encephalomyelitis; 2012.
• [31]Carruthers BM, van de Sande M, De Meirleir K, Klimas N, Broderick G, Mitchell T, Powles ACP, Speight N, Vallings R, Bateman L, Bell DS, Carlo-Stella N, Chia J, Darragh A, Gerken A, Jo D, Lewis D, Light AR, Light K, Marshall-Gradisnik S, McLaren-Howard J, Mena I, Miwa K, Murovska M, Steven S: Myalgic Encephalomyelitis - Adult & Paediatric: International Consensus Primer for Medical Practioners. Canada: Carruthers & van de Sande; 2012.
• [32]Centers for Disease Control and Prevention: CDC Chronic Fatigue Syndrome Toolkit. Atlanta, USA: CDC; 2006.
• [33]Ware JE Jr, Sherbourne CD: The MOS 36-item short-form health survey (SF-36): I. Conceptual framework and item selection. Med Care 1992, 30(6):473-483.
• [34]WHO Disability Adjustment Schedule II (WHODAS II) [http://www.who.int/icidh/whodas/index.html webcite]
• [35]Hardt J, Buchwald D, Wilks D, Sharpe M, Nix W, Egle U: Health-related quality of life in patients with chronic fatigue syndrome: an international study. J Psychosom Res 2001, 51(2):431-434.
• [36]Jason LA, Brown A, Evans M, Sunnquist M, Newton JL: Contrasting chronic fatigue syndrome versus myalgic encephalomyelitis/chronic fatigue syndrome. Fatigue: Biomedicine, Health & Behavr 2013, 1(3):168-183. ahead-of-print
• [37]World Health Organisation: International Classification of Functioning, Disability and Health (ICF). Geneva: WHO; 2002.
• [38]Brown AA, Jason LA, Evans MA , Flores S : Contrasting case definitions: the me international consensus criteria vs. the Fukuda et al. CFS criteria. N Am J Psychol 2013, 15(1):103-120.
• [39]Kennedy G, Abbot NC, Spence V, Underwood C, Belch JJ: The specificity of the CDC-1994 criteria for chronic fatigue syndrome: comparison of health status in three groups of patients who fulfill the criteria. Ann Epidemiol 2004, 14(2):95-100.
• [40]Jason LA, Taylor RR, Carrico AW: A community-based study of seasonal variation in the onset of chronic fatigue syndrome and idiopathic chronic fatigue. Chronobiol Int 2001, 18(2):315-319.
• [41]Johnston S: The role of clinical definitions in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis research. Fatigue: Biomedicine, Health & Behav 2013, 2(1):28-39.
• [42]Johnston S, Brenu EW, Staines D, Marshall-Gradisnik S: The prevalence of chronic fatigue syndrome/myalgic encephalomyelitis: a meta-analysis. Clinical Epidemiology 2013, 5:105-110.
• [43]Brenu EW, Johnston S, Hardcastle S, Huth T, Fuller K, Ramos SB, Staines D, Marshall-Gradisbik S: Comparative analysis of immune markers in chronic fatigue syndrome/myalgic Encephalomyelitis (CFS/ME) patients using two diagnostic criteria. 2013. in review
• [44]Buchwald D, Pearlman T, Umali J, Schmaling K, Katon W: Functional status in patients with chronic fatigue syndrome, other fatiguing illnesses, and healthy individuals. Am J Med 1996, 101(4):364.
• [45]Komaroff AL, Fagioli LR, Doolittle TH, Gandek B, Gleit MA, Guerriero RT, Kornish RJ II, Ware NC, Ware JE Jr, Bates DW: Health status in patients with chronic fatigue syndrome and in general population and disease comparison groups. Am J Med 1996, 101(3):281-290.
• [46]Steffen I, Tyrrell DL, Stein E, Montalvo L, Lee TH, Zhou Y, Lu K, Switzer WM, Tang S, Jia H, Hockman D, Santer DM, Logan M, Landi A, Law J, Houghton M, Simmons G: No evidence for XMRV nucleic acids, infectious virus or anti-XMRV antibodies in Canadian patients with chronic fatigue syndrome. PLoS One 2011, 6(11):e27870.
• [47]Cool M, Bouchard N, Masse G, Laganiere B, Dumont A, Hanna Z, Phaneuf D, Morisset R, Jolicoeur P: No detectable XMRV in subjects with chronic fatigue syndrome from Quebec. Virology 2011, 420(1):66-72.
• [48]Shin CH, Bateman L, Schlaberg R, Bunker AM, Leonard CJ, Hughen RW, Light AR, Light KC, Singh IR: Absence of XMRV retrovirus and other murine leukemia virus-related viruses in patients with chronic fatigue syndrome. J Virol 2011, 85(14):7195-7202.
• [49]Erlwein O, Kaye S, McClure MO, Weber J, Wills G, Collier D, Wessely S, Cleare A: Failure to detect the novel retrovirus XMRV in chronic fatigue syndrome. PLoS One 2010, 5(1):e8519.
• [50]Lombardi VC, Ruscetti FW, Das Gupta J, Pfost MA, Hagen KS, Peterson DL, Ruscetti SK, Bagni RK, Petrow-Sadowski C, Gold B, Dean M, Silverman RH, Mikovits JA: Detection of an infectious retrovirus, XMRV, in blood cells of patients with chronic fatigue syndrome. Science 2009, 326(5952):585-589.
• [51]Simmons G, Glynn SA, Komaroff AL, Mikovits JA, Tobler LH, Hackett J Jr, Tang N, Switzer WM, Heneine W, Hewlett IK, Zhao J, Lo SC, Alter HJ, Linnen JM, Gao K, Coffin JM, Kearney MF, Ruscetti FW, Pfost MA, Bethel J, Kleinman S, Holmberg JA, Busch MP: Failure to confirm XMRV/MLVs in the blood of patients with chronic fatigue syndrome: a multi-laboratory study. Science 2011, 334(6057):814-817.